Covance, Inc

Article Abstract:

The price appreciation potential of the shares of Covance Inc. for the years 2010-2012 is discussed. The Princeton, New Jersey-based company is one of the world's leading contract research organizations, and benefits from development outsourcing demand in the pharmaceutical industry.

Author: Butler, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2008

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Stock highlight: Covance, Inc. (CVD-38.58)

Article Abstract:

A leading contract research organization, Covance, is into marketing pre-clinical lab services to large pharmaceutical companies. They also undertake toxicology studies. A debt-free balance sheet, robust cash flow and over $144 million in cash assets make the stock attractive.

Author: Butler, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 2 - Selection & Opinion)
Subject: Business, general
ISSN:
Year: 2004
Commercial Banks, Investment Banking and Securities Dealing, Contracts & orders received, Portfolio Management, Contracts & orders let, Portfolio & Funds Management, Contracts, Contract agreement

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Mylan Inc

Article Abstract:

The shares of Mylan Inc. have a substantial price appreciation potential over the 2010-2012 timeframe. The Canonsburg, Pennsylvania-based company is a manufacturer of prescription generic drugs and brand-name dermatological products.

Author: Butler, Jeremy J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2008
Puerto Rico, Mylan Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Evaluation, Pharmaceutical industry, Stocks, Securities, Stock prices, Covance Inc., CVD, Company securities, Analyst report
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.